Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon
M Boussinesq, J Gardon, J Kamgno… - Annals of Tropical …, 2001 - Taylor & Francis
Ivermectin treatment may induce marked adverse effects in those harbouring> 8000 Loa
microfilariae (mff)/ml of blood, individuals with> 30 000 Loa mff/ml being at risk of developing …
microfilariae (mff)/ml of blood, individuals with> 30 000 Loa mff/ml being at risk of developing …
Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection
M Boussinesq, J Gardon - Annals of Tropical Medicine & …, 1997 - Taylor & Francis
Several cases of encephalopathy recorded in Cameroon since 1991 were in patients with
very high, coincident, Loa loa microfilaraemias who had been treated with ivermectin for …
very high, coincident, Loa loa microfilaraemias who had been treated with ivermectin for …
Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the programmes of Community-Directed Treatment with …
SDS Pion, J Gardon, J Kamgno, N Gardon-Wendel… - Parasitology, 2004 - cambridge.org
This paper describes the structure of the microfilarial reservoir of Loa loa in an endemic
population of central Cameroon. The possible effects of age and sex on the prevalence and …
population of central Cameroon. The possible effects of age and sex on the prevalence and …
Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin
M Esum, S Wanji, N Tendongfor, P Enyong - Transactions of the Royal …, 2001 - Elsevier
Encephalopathy has been reported in Cameroon in individuals heavily infected with Loa loa
microfilariae who were treated with ivermectin against onchocerciasis. Prior to the initiation …
microfilariae who were treated with ivermectin against onchocerciasis. Prior to the initiation …
[HTML][HTML] In southern Nigeria Loa loa blood microfilaria density is very low even in areas with high prevalence of loiasis: results of a survey using the new LoaScope …
E Emukah, LJ Rakers, B Kahansim, ES Miri… - The American Journal …, 2018 - ncbi.nlm.nih.gov
Ivermectin treatment can cause central nervous system adverse events (CNS-AEs) in
persons with very high-density Loa loa microfilaremia (≥ 30,000 mf/mL blood) …
persons with very high-density Loa loa microfilaremia (≥ 30,000 mf/mL blood) …
Combined utilisation of rapid assessment procedures for loiasis (RAPLOA) and onchocerciasis (REA) in rain forest villages of Cameroon
S Wanji, N Tendongfor, M Esum, SSJ Yundze… - Filaria journal, 2005 - Springer
Background Individuals with high microfilarial loads of Loa loa are at increased risk of
neurologic serious adverse (SAE) events following ivermectin treatment against …
neurologic serious adverse (SAE) events following ivermectin treatment against …
Mapping the distribution of Loa loain Cameroon in support of the African Programme for Onchocerciasis Control
Background Loa loa has recently emerged as a filarial worm of significant public health
importance as a consequence of its impact on the African Programme for Onchocerciasis …
importance as a consequence of its impact on the African Programme for Onchocerciasis …
Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting?
SDS Pion, P Clarke, JAN Filipe, J Kamgno, J Gardon… - Parasitology, 2006 - cambridge.org
Ivermectin treatment may induce severe adverse reactions in some individuals heavily
infected with Loa loa. This hampers the implementation of mass ivermectin treatment against …
infected with Loa loa. This hampers the implementation of mass ivermectin treatment against …
Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria
Background Loiasis is currently receiving attention as a disease of public health importance
because of the possibility of increased risk of developing neurologic serious adverse event …
because of the possibility of increased risk of developing neurologic serious adverse event …
Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (∼25 μg/kg) versus current standard dose (150 μg/kg)
J Kamgno, SDS Pion, MC Tejiokem… - Transactions of the …, 2007 - academic.oup.com
Neurological serious adverse events (SAEs) following ivermectin treatment may occur in
individuals harbouring high Loa loa microfilarial densities and are of major concern in the …
individuals harbouring high Loa loa microfilarial densities and are of major concern in the …